| scholarly article | Q13442814 |
| P2093 | author name string | Jian Chen | |
| Wei Wang | |||
| Lei Zhu | |||
| Bing Hu | |||
| Chu-Shu Ji | |||
| Yi-Fu He | |||
| Chang-Lu Hu | |||
| Feng-Shou Jiang | |||
| Yi-Wei Yao | |||
| Ping-Sheng Fan | |||
| P2860 | cites work | Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 |
| Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer | Q33360840 | ||
| A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group | Q33364027 | ||
| A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus | Q33367577 | ||
| Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer | Q33367836 | ||
| Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer | Q33374495 | ||
| Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer | Q33375553 | ||
| Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer | Q33375668 | ||
| A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma | Q33376462 | ||
| A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer | Q33384922 | ||
| Oesophageal cancer: new developments in systemic therapy | Q35571246 | ||
| Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer | Q36614893 | ||
| Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer | Q36644156 | ||
| Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma | Q36694794 | ||
| A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus | Q39321695 | ||
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 | ||
| In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines | Q40426495 | ||
| Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin | Q41658048 | ||
| Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel | Q43762411 | ||
| Treatment outcomes of resected esophageal cancer | Q43920736 | ||
| Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study | Q44715314 | ||
| Primary esophageal adenocarcinoma--report of 19 cases | Q45096515 | ||
| Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma | Q45127730 | ||
| Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma | Q46219960 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation | Q46633866 | ||
| Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices | Q68822249 | ||
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus | Q72683495 | ||
| In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers | Q73267090 | ||
| Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | Q73707393 | ||
| Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus | Q74545971 | ||
| A phase II study of carboplatin and paclitaxel in esophageal cancer | Q80107223 | ||
| [Chemotherapy to patients with metastatic carcinoma of the esophagus and gastro-esophageal junction. A survey of a Cochrane review] | Q80948662 | ||
| P433 | issue | 35 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | paclitaxel | Q423762 |
| esophageal squamous cell carcinoma | Q108442577 | ||
| P304 | page(s) | 5910-5916 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | A phase II study of paclitaxel and nedaplatin as front-line chemotherapy in Chinese patients with metastatic esophageal squamous cell carcinoma | |
| P478 | volume | 19 |
| Q33433296 | A Retrospective Comparison of Taxane and Fluorouracil-based Chemoradiotherapy in Patients with Inoperable Esophageal Squamous Cell Carcinoma |
| Q37407348 | Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition |
| Q42371500 | Nestin expression involves invasiveness of esophageal carcinoma and its downregulation enhances paclitaxel sensitivity to esophageal carcinoma cell apoptosis |
| Q37382552 | Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer |
| Q33608780 | Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells |
| Q38922051 | Silencing stathmin-modulating efficiency of chemotherapy for esophageal squamous cell cancer with paclitaxel |
| Q92182613 | The human amniotic fluid mesenchymal stem cells therapy on, SKOV3, ovarian cancer cell line |
Search more.